Further, the analysis of patients with low intratumoral expression levels of IL-17A (87 ± 14 months) showed a trend to reduced survival times compared to patients with high intratumoral IL-17A expression (117 ± 11 months) though the difference was not statistically significant (P = 0.211) (Figure 6 B).
← all excerpts
Neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETS TNM-classification and immunohistochemical markers for risk stratification.
1
—
—